Human Microbiome Market Share

  • Report ID: 4062
  • Published Date: Sep 09, 2025
  • Report Format: PDF, PPT

Human Microbiome Market Regional Analysis:

North American Market Insights

The human microbiome market in North America is poised to account for the largest share of 35% by the end of 2035, driven by rising pet adoption. The rising frequency of lifestyle illnesses in developed countries such as the United States is boosting the demand for microbiome-related goods and services, as people look for ways to enhance their gut health and overall health outcomes. According to data, the prevalence of age- and lifestyle-related diseases in the US is forecasted to rise by more than 15% over the next 20 years. Hence, the human microbiome market in North America will expand during the forecast period with an increase in government initiatives to enable the study of microbial communities to improve understanding of the microbiota and support human health in the region.

Europe Market Forecast  Insights

The Europe human microbiome market is estimated to be the second largest regional market with a share of about 25% by the end of 2035. The growth in research & development (R&D) activities for new applications of the human microbiome and the long-term vision of developing a life science ecosystem with the rising investments for biomedical research is predicted to expand the market in the region.

Human Microbiome Market size

Browse key industry insights with market data tables & charts from the report:

Frequently Asked Questions (FAQ)

In the year 2026, the industry size of human microbiome is assessed at USD 1.66 billion.

The global human microbiome market size was valued at around USD 1.37 billion in 2025 and is projected to grow at a CAGR of more than 23.5%, reaching USD 11.31 billion revenue by 2035.

North America human microbiome market will hold around 35% share by 2035, driven by rising pet adoption and increasing prevalence of lifestyle diseases.

Key players in the market include Seres Therapeutics, Inc., Evelo Biosciences, Inc., Synlogic, Inc., Second Genome Inc., Synthetic Biologics, Inc., YSOPIA Bioscience, 4D Pharma plc, DuPont de Nemours, Inc., BiomX Inc., Sun Genomics, Inc., Viome Life Sciences, Inc.
Inquiry Before Buying Request Free Sample PDF
footer-bottom-logos